DeepMed Research

West China Hospital of Sichuan University (Sichuan International Hospital)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy

Phase 2

Recruiting

Conditions: Postoperative Chronic Pain

Interventions: Drug: Lidocaine Hydrochloride, Injectable
Drug: 0.9% normal saline

First Posted Date: 2022-08-08

Last Posted Date: 2024-04-19

Lead Sponsor: West China Hospital

Target Recruit Count: 260

Registration Number: NCT05492669

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Camrelizumab
Drug: Apatinib
Drug: Nab-paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2022-07-07

Last Posted Date: 2023-05-22

Lead Sponsor: West China Hospital

Target Recruit Count: 35

Registration Number: NCT05447702

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer

Not Applicable

Recruiting

Conditions: Prostate Cancer
Stereotactic Body Radiotherapy
Safety
High-risk
Efficacy

Interventions: Radiation: stereotactic body radiotherapy

First Posted Date: 2022-06-24

Last Posted Date: 2022-06-24

Lead Sponsor: West China Hospital

Target Recruit Count: 60

Registration Number: NCT05430737

Locations: 🇨🇳
China, SiChuan, Chengdu, Sichuan, China

a Pilot Study of Lidocaine Infusion for Postoperative Analgesia in Elderly Patients With Colorectal Cancer Surgery

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Lidocaine Hydrochloride 2% Injection Solution
Drug: 0.9% NaCl

First Posted Date: 2022-06-09

Last Posted Date: 2024-03-13

Lead Sponsor: West China Hospital

Target Recruit Count: 220

Registration Number: NCT05412576

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis

Phase 2

Recruiting

Conditions: Probiotics
Glutamine
Bifidobacterium
Radiation Proctitis
Gut Microbiota

Interventions: Drug: Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules

First Posted Date: 2022-06-07

Last Posted Date: 2022-07-15

Lead Sponsor: West China Hospital

Target Recruit Count: 176

Registration Number: NCT05406882

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China
🇨🇳
Xin Wang, Chengdu, Sichuan, China

Dynamics of Immune Map and Outcomes After On-pump Cardiac Surgery: Protocol for a Prospective Cohort Study

Recruiting

Conditions: On-pump Valve Surgery or CABG

Interventions: Procedure: On-pump valve surgery or CABG

First Posted Date: 2022-06-01

Last Posted Date: 2023-02-22

Lead Sponsor: West China Hospital

Target Recruit Count: 120

Registration Number: NCT05400356

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients

Not Applicable

Conditions: Liver Cancer

Interventions: Drug: Lidocaine Hydrochloride, Injectable

First Posted Date: 2022-05-11

Last Posted Date: 2022-05-11

Lead Sponsor: West China Hospital

Target Recruit Count: 120

Registration Number: NCT05369650

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol

Recruiting

Conditions: Coronary Artery Disease

First Posted Date: 2022-05-11

Last Posted Date: 2023-02-16

Lead Sponsor: West China Hospital

Target Recruit Count: 1300

Registration Number: NCT05369442

Locations: 🇨🇳
West China Hospital, Sichuan University, Sichuan, Sichuan, China

Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

Phase 2

Recruiting

Conditions: Hemangioendothelioma

Interventions: Drug: Sirolimus

First Posted Date: 2022-04-12

Last Posted Date: 2024-01-24

Lead Sponsor: West China Hospital

Target Recruit Count: 30

Registration Number: NCT05324384

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)

Phase 1

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Sapropterin dihydrochloride tablets

First Posted Date: 2022-03-28

Last Posted Date: 2022-03-28

Lead Sponsor: West China Hospital

Target Recruit Count: 18

Registration Number: NCT05299203

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy